HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.

AuthorsTongyan Meng, Yao Yao, Yang Xu, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Depei Wu, Yanming Zhang, Ying Wang
JournalHematological oncology (Hematol Oncol) Vol. 38 Issue 5 Pg. 834-837 (Dec 2020) ISSN: 1099-1069 [Electronic] England
PMID32710795 (Publication Type: Letter)
Chemical References
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Aclarubicin
  • Decitabine
Topics
  • Aclarubicin (pharmacology, therapeutic use)
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
  • Cytarabine (pharmacology, therapeutic use)
  • Decitabine (pharmacology, therapeutic use)
  • Female
  • Granulocyte Colony-Stimulating Factor (pharmacology, therapeutic use)
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, mortality)
  • Salvage Therapy (methods)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: